Meliglix 50 Mg

Sitagliptin, the active ingredient in Meliglix 50 Mg, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a 50 mg tablet for oral administration. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, often as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Meliglix 50 Mg as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated channels and supporting customers with documentation, logistics and quality assurance.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose.

Type 2 diabetes mellitus (monotherapy): improves glycaemic control when diet and exercise alone are insufficient. Type 2 diabetes mellitus (combination therapy): used together with metformin or other oral agents to achieve target glucose levels. Type 2 diabetes mellitus (adjunct to lifestyle): supports blood‑sugar management alongside diet and exercise.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient head discomfort. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Gastrointestinal upset: nausea, abdominal pain or dyspepsia. - Dizziness: occasional light‑headed sensation. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Acute renal failure: sudden loss of kidney function.

Before initiating therapy, consider the following precautions: - Renal function assessment: adjust dose in patients with impaired renal function. - Monitor blood glucose: watch for hypoglycaemia when combined with insulin or sulfonylureas. - Cardiovascular risk: evaluate in patients with a history of heart failure. - Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. - Elderly patients: start at a lower dose and monitor for adverse reactions. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Sitagliptin may interact with several medicines. Review the following categories: Major Interactions (Avoid): - Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma concentrations. Moderate Interactions (Monitor Closely): - Diuretics such as furosemide: may reduce antihyperglycaemic efficacy. - Rifampin: can lower sitagliptin levels, potentially reducing effectiveness. - ACE inhibitors: monitor renal function and electrolytes. - Warfarin: periodic INR monitoring is advised.